Our analysis showed that some subtypes of macrophages gene sets were significantly enriched in partial response (PR) or complete response (CR) patient groups in both thymic and NSCLCs after anti-PD-1 treatment, suggesting that anti-PD-1 therapy may be an effective approach for tumor immunotherapy. This evidence concerns the gene RPL17 and neoplasm.